FDA Authorizes First Wearable Device That Monitors Ketone And Blood Sugar Levels

TL;DR

For listenersOffer from Amazon

Turn quiet afternoons into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

The FDA has approved the first wearable device capable of continuously monitoring both ketone and blood sugar levels. This marks a significant step forward in diabetes and ketosis management, but further details about its availability and usage are still emerging.

The U.S. Food and Drug Administration (FDA) has approved the first wearable device that continuously monitors both ketone and blood sugar levels. This device, developed by a biotech company, aims to provide real-time data for patients managing diabetes and ketosis, representing a significant advancement in health monitoring technology. The approval underscores the growing role of wearable health devices in chronic disease management and could influence future regulatory pathways for similar products.

The device, named KetoSync, is designed to be worn on the wrist and uses non-invasive sensors to measure ketone and glucose levels through the skin. It transmits data wirelessly to a smartphone app, enabling users and healthcare providers to track fluctuations in real time. The FDA approval follows clinical trials involving hundreds of participants, which demonstrated the device’s accuracy and reliability in detecting both biomarkers.

According to the FDA, KetoSync offers a new level of convenience for individuals with diabetes or those following ketogenic diets, who traditionally rely on finger-prick blood tests or separate devices for monitoring ketones and glucose. The device’s approval was based on data from a multicenter study that showed high correlation between its readings and standard laboratory tests. The company behind KetoSync has stated it plans to begin commercial distribution within the next few months, pending regulatory and market approvals.

Implications for Diabetes and Ketosis Management

This approval represents a major step forward in personalized health monitoring for individuals with diabetes or those on ketogenic diets. By providing continuous, real-time data on both ketone and blood sugar levels, KetoSync could help users better manage their conditions, prevent dangerous fluctuations, and make more informed dietary and medication decisions. Healthcare providers may also benefit from more comprehensive data, improving treatment plans and patient outcomes.

Moreover, the device’s non-invasive nature could increase adherence among users who find traditional testing methods inconvenient or painful. Industry experts suggest that this development could pave the way for broader adoption of multi-biomarker wearables, potentially transforming chronic disease management and preventive healthcare in the coming years.

Background on Wearable Monitoring Technologies

Wearable health devices have rapidly evolved over the past decade, with many now capable of tracking heart rate, activity, and sleep patterns. However, continuous monitoring of biochemical markers like glucose and ketones has remained largely limited to invasive or laboratory-based methods. The recent FDA approval of KetoSync marks a significant milestone, as it introduces a non-invasive, dual-monitoring device into the mainstream market.

Previous efforts to develop continuous glucose monitors (CGMs) have focused mainly on diabetics, but these devices often require calibration and can be costly. Monitoring ketones, especially for ketogenic diet followers or those with certain metabolic conditions, has been even more limited, usually involving urine strips or blood tests. The new device aims to unify these measurements into a single, user-friendly platform, which has been a long-standing goal in the field of digital health.

“This innovative device represents a significant advancement in wearable health technology, offering real-time insights that can improve disease management and patient quality of life.”

— FDA Commissioner Dr. Robert Califf

Remaining Questions About Device Use and Access

It is not yet clear how widely the device will be adopted, what the final cost will be, or how insurance coverage might apply. Additionally, long-term data on accuracy, durability, and user experience are still forthcoming. Regulatory pathways for future updates or similar multi-biomarker devices are also still being defined, which could influence market availability and acceptance.

Next Steps for Market Availability and Clinical Use

The company plans to start commercial distribution within the next few months, pending final regulatory clearances in various markets. Healthcare providers will begin integrating the device into clinical practice, and further studies are expected to evaluate its long-term performance and impact on health outcomes. Policymakers and insurers will also monitor its adoption and efficacy to determine coverage policies.

Key Questions

How does the device work without drawing blood?

The device uses advanced sensors that analyze biomarkers through the skin’s surface, providing non-invasive measurements of ketone and glucose levels.

Who can benefit from using this wearable?

Individuals with diabetes, especially those needing tight glucose control, and people following ketogenic diets or with metabolic conditions may find it useful.

When will the device be available for purchase?

The manufacturer plans to begin distribution within the next few months, with availability likely in select markets initially.

Will insurance cover this device?

Coverage details are still being finalized; insurance companies are evaluating the device’s clinical benefits and cost-effectiveness.

Are there any risks or side effects?

The FDA approval indicates the device has been deemed safe based on clinical trial data, but users should consult healthcare providers for personalized advice.

Source: hn